NCT03435289 - A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

November 30, 2018

Study Completion Date

January 31, 2019

Conditions

Pancreatic CancerMetastatic Pancreatic Cancer

Interventions

DRUG

CPI 613 in Combination With Gemcitabine and Nab-paclitaxel

"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"

Trial Locations (2)

07960

RECRUITING

Morristown Medical Center, Morristown

07901

RECRUITING

Overlook Medical Center, Summit